Cancer Immunotherapy: An Effective Tool in Cancer Control and Treatment

Author(s): Kawalpreet Kaur, Gopal L. Khatik*.

Journal Name: Current Cancer Therapy Reviews

Volume 16 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Cancer immunotherapy is a type of cancer treatment which effectively harnesses the natural ability of the immune system to fight against cancer cells. This approach takes into consideration the fact that cancer cells express various types of antigens on their surface. Such tumor antigens can be detected by the immune system. However, cancer cells normally develop resistance to the defensive mechanisms presented by the immune system. Thus, cancer immunotherapy has some challenges in its path but due to its impressive clinical effectiveness, it is considered as the potential and effective mode of treatment for cancer.

Methods: We searched the scientific database using cancer, immunotherapy, and tumor antigens as the keywords. Herein, only peer-reviewed research articles were collected which were useful to our current work.

Results: Cells responsible for incurring natural immunity to the body are engineered in such a way that they become able to efficiently recognize and bind to tumor antigens. Such type of immunotherapy is referred to as active immunotherapy. Another type is passive immunotherapy, which involves the process of modifying the existing natural immune responses against cancer cells. A hybrid type of immunotherapy has also been developed which involves the combinative use of both active and passive immunotherapy. Cancer immunotherapy has so far proven to be an effective treatment for cancer as this therapy primarily aims at attacking cancer cells and not the healthy body cells lying in close vicinity to them.

Conclusion: In the review, we described the significance of immunotherapy in the management of various types of cancer.

Keywords: Cancer, immunotherapy, tumor antigens, active immunotherapy, passive immunotherapy, pathogens.

[1]
Parkin J, Cohen B. An overview of the immune system. Lancet 2001; 357(9270): 1777-89.
[http://dx.doi.org/10.1016/S0140-6736(00)04904-7] [PMID: 11403834]
[2]
Chen I. Immunotherapy in cancer treatment: A review of checkpoint inhibitors. US Pharm 2018; 43: 27-31.
[3]
Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: The beginning of the end of cancer? BMC Med 2016; 14: 73.
[http://dx.doi.org/10.1186/s12916-016-0623-5] [PMID: 27151159]
[4]
Rosenberg SA. The emergence of modern cancer immunotherapy. Ann Surg Oncol 2005; 12(5): 344-6.
[http://dx.doi.org/10.1245/ASO.2005.01.904] [PMID: 15843873]
[5]
Oiseth SJ, Aziz MS. Cancer immunotherapy: A brief review of the history, possibilities, and challenges ahead. J Cancer Metastasis Treat 2017; 3: 250-61.
[http://dx.doi.org/10.20517/2394-4722.2017.41]
[6]
Saey TH, Cunningham A. Discovery of how to prod a patient’s immune system to fight cancer wins a Nobel Sci News 2018; Available from: https://www.sciencenews.org/article/how-prod-patient-immune-system-fight-cancer-wins-nobel-prize (Accessed on: October 1, 2018).
[7]
Nouri Rouzbahani F, Shirkhoda M, Memari F, et al. Immunotherapy a new hope for cancer treatment: A review. Pak J Biol Sci 2018; 21(3): 135-50.
[http://dx.doi.org/10.3923/pjbs.2018.135.150] [PMID: 30187723]
[8]
Fuge O, Vasdev N, Allchorne P, Green JS. Immunotherapy for bladder cancer. Res Rep Urol 2015; 7: 65-79.
[PMID: 26000263]
[9]
Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol 2015; 35(Suppl.): S185-98.
[http://dx.doi.org/10.1016/j.semcancer.2015.03.004] [PMID: 25818339]
[10]
Triplett TA, Garrison KC, Marshall N, et al. Reversal of IDO-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme. Nat Biotechnol 2018; 36(8): 758-64.https://www.ncbi.nlm.nih.gov/pubmed/30010674
[http://dx.doi.org/10.1038/nbt.4180]
[11]
Nagasawa DT, Fong C, Yew A, et al. Passive immunotherapeutic strategies for the treatment of malignant gliomas. Neurosurg Clin N Am 2012; 23(3): 481-95.
[http://dx.doi.org/10.1016/j.nec.2012.04.008] [PMID: 22748660]
[12]
Schmidt C. The benefits of immunotherapy combinations. Nature 2017; 552(7685): S67-9.
[http://dx.doi.org/10.1038/d41586-017-08702-7] [PMID: 29293245]
[13]
Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2017; 377(14): 1345-56.
[http://dx.doi.org/10.1056/NEJMoa1709684] [PMID: 28889792]
[14]
Elshahidi M. Immune checkpoint inhibitors and health-related quality of life: A systematic review of the current literature. Mustansiriya Med J 2018; 17: 1-14.
[http://dx.doi.org/10.4103/MJ.MJ_19_18]
[15]
Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: Recent progress and potential biomarkers. Exp Mol Med 2018; 50(12): 165.
[http://dx.doi.org/10.1038/s12276-018-0191-1] [PMID: 30546008]
[16]
Subrahmanyam PB, Dong Z, Gusenleitner D, et al. Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. J Immunother Cancer 2018; 6(1): 18.
[http://dx.doi.org/10.1186/s40425-018-0328-8] [PMID: 29510697]
[17]
Kokate R. A systematic overview of cancer immunotherapy: An emerging therapy. Pharm Pharmacol Int J 2017; 5: 31-5.
[http://dx.doi.org/10.15406/ppij.2017.05.00112]
[18]
Burgdorf SK, Fischer A, Myschetzky PS, et al. Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. Oncol Rep 2008; 20(6): 1305-11.
[PMID: 19020707]
[19]
Fenton RG, Longo DL. Genetic instability and tumor cell variation: Implications for immunotherapy. J Natl Cancer Inst 1995; 87(4): 241-3.
[http://dx.doi.org/10.1093/jnci/87.4.241] [PMID: 7707413]
[20]
Espinoza-Delgado I. Cancer vaccines. Oncologist 2002; 7(Suppl. 3): 20-33.
[http://dx.doi.org/10.1634/theoncologist.7-suppl_3-20] [PMID: 12165652]
[21]
Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4(3): 321-7.
[http://dx.doi.org/10.1038/nm0398-321] [PMID: 9500606]
[22]
Mukherji B, Chakraborty NG, Yamasaki S, et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995; 92(17): 8078-82.
[http://dx.doi.org/10.1073/pnas.92.17.8078] [PMID: 7644541]
[23]
Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4(3): 328-32.
[http://dx.doi.org/10.1038/nm0398-328] [PMID: 9500607]
[24]
Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci 2016; 107(10): 1373-9.
[http://dx.doi.org/10.1111/cas.13027] [PMID: 27486853]
[25]
Jaime-Ramirez AC, Yu JG, Caserta E, et al. Reolysin and histone deacetylase inhibition in the treatment of head and neck squamous cell carcinoma. Mol Ther Oncolytics 2017; 5: 87-96.
[http://dx.doi.org/10.1016/j.omto.2017.05.002] [PMID: 28812060]
[26]
Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252(5007): 854-6.
[http://dx.doi.org/10.1126/science.1851332] [PMID: 1851332]
[27]
Sun TY, Wang Q, Zhang J, Wu T, Zhang F. Trastuzumab-Peptide interactions: Mechanism and application in structure-based ligand design. Int J Mol Sci 2013; 14(8): 16836-50.
[http://dx.doi.org/10.3390/ijms140816836] [PMID: 23955267]
[28]
Davar D, Ding F, Saul M, et al. High-dose interleukin-2 (HD IL-2) for advanced melanoma: A single center experience from the University of Pittsburgh Cancer Institute. J Immunother Cancer 2017; 5(1): 74.
[http://dx.doi.org/10.1186/s40425-017-0279-5] [PMID: 28923120]
[29]
Achkar T, Arjunan A, Wang H, et al. High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features. PLoS One 2017; 12(12)e0190084
[http://dx.doi.org/10.1371/journal.pone.0190084] [PMID: 29261796]
[30]
Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8(4): 299-308.
[http://dx.doi.org/10.1038/nrc2355] [PMID: 18354418]
[31]
Marmarelis ME, Aggarwal C. Combination immunotherapy in non-small cell lung cancer. Curr Oncol Rep 2018; 20(7): 55.
[http://dx.doi.org/10.1007/s11912-018-0697-7] [PMID: 29740718]
[32]
Miliotou AN, Papadopoulou LC. CAR T-cell therapy: A new era in cancer immunotherapy. Curr Pharm Biotechnol 2018; 19(1): 5-18.
[http://dx.doi.org/10.2174/1389201019666180418095526] [PMID: 29667553]
[33]
Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013; 3(4): 388-98.
[http://dx.doi.org/10.1158/2159-8290.CD-12-0548] [PMID: 23550147]
[34]
Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371(16): 1507-17.
[http://dx.doi.org/10.1056/NEJMoa1407222] [PMID: 25317870]
[35]
Wang Z, Wu Z, Liu Y, Han W. New development in CAR-T cell therapy. J Hematol Oncol 2017; 10(1): 53.
[http://dx.doi.org/10.1186/s13045-017-0423-1] [PMID: 28222796]
[36]
Wang CM, Wu ZQ, Wang Y, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: An open-label phase 1 trial. Clin Cancer Res 2017; 23(5): 1156-66.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-1365] [PMID: 27582488]
[37]
Daher M, Rezvani K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol 2018; 51: 146-53.
[http://dx.doi.org/10.1016/j.coi.2018.03.013] [PMID: 29605760]
[38]
Willemsen RA, Debets R, Chames P, Bolhuis RL. Genetic engineering of T cell specificity for immunotherapy of cancer. Hum Immunol 2003; 64(1): 56-68.
[http://dx.doi.org/10.1016/S0198-8859(02)00730-9] [PMID: 12507815]
[39]
Cross D, Burmester JK. Gene therapy for cancer treatment: Past, present and future. Clin Med Res 2006; 4(3): 218-27.
[http://dx.doi.org/10.3121/cmr.4.3.218] [PMID: 16988102]
[40]
Ventola CL. Cancer Immunotherapy, Part 3: Challenges and future trends. P&T 2017; 42(8): 514-21.
[PMID: 28781505]
[41]
Riley JL. PD-1 signaling in primary T cells. Immunol Rev 2009; 229(1): 114-25.
[http://dx.doi.org/10.1111/j.1600-065X.2009.00767.x] [PMID: 19426218]
[42]
Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015; 14(4): 847-56.
[http://dx.doi.org/10.1158/1535-7163.MCT-14-0983] [PMID: 25695955]
[43]
Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L. Current challenges in cancer treatment. Clin Ther 2016; 38(7): 1551-66.
[http://dx.doi.org/10.1016/j.clinthera.2016.03.026] [PMID: 27158009]
[44]
Pardoll D. Cancer and the immune system: Basic concepts and targets for intervention. Semin Oncol 2015; 42(4): 523-38.
[http://dx.doi.org/10.1053/j.seminoncol.2015.05.003] [PMID: 26320058]
[45]
Gunturu KS, Woo Y, Beaubier N, Remotti HE, Saif MW. Gastric cancer and trastuzumab: first biologic therapy in gastric cancer. Ther Adv Med Oncol 2013; 5(2): 143-51.
[http://dx.doi.org/10.1177/1758834012469429] [PMID: 23450234]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 1
Year: 2020
Page: [62 - 69]
Pages: 8
DOI: 10.2174/1573394715666190913184853

Article Metrics

PDF: 23
HTML: 5